Medtronic (NYSE:MDT) completed the previously announced acquisition of China Kanghui Holdings in a deal valuing the company at $30.75 per share, for a total transaction value of $816 million.
Wall Street Beat
Cleveland HeartLab pulls in $15M | Wall Street Beat
Cleveland HeartLab pulled in $14.7 million in equity financing for its proprietary test for cardiac inflammation, according to a regulatory filing.
The CardioMPO test was developed by Dr. Stanley Hazen, director of the Cleveland Clinic’s center for cardiovascular diagnostics and prevention.
Cleveland HeartLab closed a $3 million round in 2010, with backers including Glengary and Second Generation Ltd.
Abiomed plunges 30% on federal investigation into Impella marketing
Robotics: Hansen gains 25% on $30M deal with Intuitive Surgical
Wall Street shuts down for 2nd day | Wall Street Beat
The New York Stock Exchange was closed for a 2nd day today for the 1st time in 124 years, after Hurricane Sandy had its way with lower Manhattan yesterday. The storm also took out the NASDAQ exchange.
The Category I hurricane killed at least 108 people as is raged up the Eastern Seaboard from the Caribbean, 39 of them in the U.S.
The NYSE and NASDAQ said they plan to re-open tomorrow.
A drab quarter for Cardinal Health’s medical device business
Cardinal Health (NYSE:CAH) reported disappointing numbers for its medical device business during the company’s 1st quarter, citing volume softness that led to a 6% dip in profit.
Medical device revenues amounted to just under $2.4 billion during the 3 months ended Sept. 30, 2012, representing a 1% increase year-over-year.
Merit Medical posts record profit with a Street-beating Q3
Medical devices maker Merit Medical (NSDQ:MMSI) posted a Wall Street-beating net income for its 3rd quarter, contributing to 9-month earnings higher than the company’s ever had before.
Greatbatch slips to loss in Q3 with Swiss plant closure costs
Medical device maker Greatbatch (NYSE:GB) lost $7.6 million in 3Q, the result of the nearly $15 million in expense to close a pair of Swiss factories.
Haemonetics’ double-digit growth blows away Wall Street’s expectations
Haemonetics (NYSE:HAE) turned things around in its 2nd quarter, blowing away Wall Street analysts’ expectations with per-share diluted earnings more than 16% beyond consensus estimates.
Endologix narrows losses amid strong sales growth in Q3
Endologix (NSDQ:ELGX) made progress in its 3rd quarter, narrowing losses despite a $5 million lawsuit loss to Cook Medical.
EnteroMedics cuts losses in Q3, aims for 2014 commercialization
EnteroMedics (NSDQ:ETRM) narrowed its losses during its 3rd quarter, cutting its research & development expenses nearly in half.